Status:
COMPLETED
Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Cerebral Amyloid Angiopathy
Eligibility:
All Genders
55+ years
Phase:
NA
Brief Summary
Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in the elderly with high risk of recurrence. The investigators aim to determine the relationship between cor...
Detailed Description
Patients with acute lobar ICH fulfilling the Boston criteria for probable or possible CAA will be enrolled within 30 days after ICH onset. Brain MRI performed at baseline will be analyzed blinded to c...
Eligibility Criteria
Inclusion
- Lobar ICH within 30 days after onset
- Available brain MRI sequences of adequate quality including fluid-attenuated inversion recovery (FLAIR) and T2\*-weighted gradient-recalled echo (T2\*-GRE) sequences.
- Modified Boston criteria for probable or possible CAA
- Age ≥ 55 years
- Written consent
Exclusion
- Secondary brain hemorrhage : vascular malformation (arteriovenous malformation, aneurysm, cavernous); cerebral veinous thrombosis; brain tumor; coagulopathy; vasculitis; hemorrhagic infarction,
- Infratentorial siderosis
- Contraindications to MRI
- Neurosurgical intervention before inclusion,
- Progressive neoplasm
- Patient without affiliation to the french social security
- Patient under guardianship
Key Trial Info
Start Date :
October 12 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 11 2025
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT03464344
Start Date
October 12 2018
End Date
February 11 2025
Last Update
December 31 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pellegrin Hospital
Bordeaux, France
2
Gui de Chauliac Hospital
Montpellier, France
3
Lariboisière Hospital
Paris, France
4
CHU Purpan. Hôpital Pierre-Paul Riquet
Toulouse, France, 31059